Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Nonsteroidal Anti-Androgens

Known as: Anti-Androgens, Nonsteroidal, AntiAndrogens, Nonsteroidal, Nonsteroidal Anti Androgens 
Nonsteroidal agents which block the action or downregulate the synthesis of ANDROGENS.
National Institutes of Health

Related topics

Related topics

5 relations
In Bloodagonistsaspects of radiation effectschemical synthesis
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Metastatic prostate cancer is treated with drugs that antagonize androgen action, but most patients progress to a more aggressive… Expand
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
PURPOSE Large meta-analyses have documented that maximum androgen blockade with nonsteroidal antiandrogens for advanced prostate… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Review
2008
Review
2008
Androgen cell signaling pathways involved in neuroprotective actions
As a normal consequence of aging in men, testosterone levels significantly decline in both serum and brain. Age-related… Expand
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells.
PURPOSE Androgen deprivation is implicated in reducing neoangiogenesis in prostate cancer (PCA). Androgens regulate the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
1997
1997
Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic…
OBJECTIVES To evaluate the short- and long-term effects of neoadjuvant hormonal treatment in locally confined prostate cancer… Expand
  • table I
  • table II
Is this relevant?
Highly Cited
1997
Highly Cited
1997
Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens.
OBJECTIVES To assess the survival benefit of maximum androgen blockade (MAB) using nonsteroidal antiandrogens (NSAAs) through… Expand
Is this relevant?
1995
1995
Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome.
We report a dramatic decrease in prostate specific antigen in response to the discontinuation of megestrol acetate in a patient… Expand
Is this relevant?
Highly Cited
1993
Highly Cited
1993
Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone.
Structural changes of the androgen receptor (AR) may contribute to the development of resistance to endocrine therapy in… Expand
Is this relevant?
Highly Cited
1993
Highly Cited
1993
Transcriptional and posttranscriptional regulation of human androgen receptor expression by androgen.
Autoregulation is a control mechanism common to several proteins of the steroid/thyroid hormone receptor superfamily. In this… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
Is this relevant?
1991
1991
Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project.
A total of 26 previously untreated patients with metastatic carcinoma of the prostate received the pure nonsteroidal antiandrogen… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE